Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The collaboration marks a critical step in advancing the company’s chemistry, manufacturing and controls (CMC) strategy for the oncology drug candidate.
The work scope includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement and manufacturing scalability assessments. These activities are intended to establish a scalable, reproducible and analytically characterized polymer platform that will underpin future formulation, manufacturing, regulatory and clinical development efforts. Onco-Innovations stated that Nanosoft’s expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform while supporting future GMP manufacturing readiness.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors. The ONC010 program leverages nanoparticle technology to deliver a PNKP inhibitor, an enzyme involved in DNA repair pathways that cancer cells rely on for survival. By inhibiting PNKP, ONC010 may enhance the effectiveness of radiation and chemotherapy.
The importance of this announcement lies in the transition from early-stage research to manufacturing development. Establishing a robust and scalable manufacturing process is essential for advancing ONC010 into clinical trials and ultimately to regulatory approval. The partnership with Nanosoft Polymers, a specialist in polymer science, provides Onco-Innovations with the technical capabilities needed to overcome common challenges in nanoparticle drug development, such as batch-to-batch reproducibility and stability.
For investors, the progress in CMC activities signals that Onco-Innovations is moving closer to clinical-stage development. The company’s focus on solid tumors addresses a significant unmet medical need, and the nanoparticle formulation could offer advantages over traditional therapies, including targeted delivery and reduced side effects. The full press release is available at https://nnw.fm/BeSoS.
Onco-Innovations continues to build momentum in its oncology pipeline. With the support of Nanosoft, the company aims to de-risk the manufacturing process and prepare for the next phase of drug development. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF.
